SCHEMBL3412973

SCHEMBL3412973

CC(C)(C)NC(=O)Nc1ccc2nc(N[C@@H]3CCc4ccccc43)ccc2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRS3 P32247 1/20 0.47
ALDH1A1 P00352 3/20 0.45
NPC1 O15118 2/20 0.45
KDM4E B2RXH2 2/20 0.45
TP53 P04637 1/20 0.45
GAA P10253 1/20 0.45
HPGD P15428 1/20 0.45
CASP1 P29466 1/20 0.45
RAB9A P51151 1/20 0.45
CASP7 P55210 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
HSD17B10 Q99714 1/20 0.45
ANO1 Q5XXA6 3/20 0.43
LMNA P02545 2/20 0.42
NPY1R P25929 1/20 0.42
HPGDS O60760 1/20 0.40
MAPK13 O15264 1/20 0.40
MAPK12 P53778 1/20 0.40
MAPK11 Q15759 1/20 0.40
MAPK14 Q16539 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3411790 0.89 NPC1 (0.42) BRS3ALDH1A1NPC1LMNANPY1R
SCHEMBL4106006 0.88 HPGDS (0.41) BRS3ALDH1A1NPC1TP53GAA
SCHEMBL3403165 0.88 KMT2A (0.48) ALDH1A1NPC1RAB9ALMNAHPGDS
SCHEMBL4109902 0.87 MAPT (0.44) ALDH1A1NPC1KDM4ERAB9AHPGDS
SCHEMBL3410563 0.86 NPY1R (0.48) ALDH1A1NPC1NPY1RKMT2A
SCHEMBL3412407 0.86 JAK2 (0.47) ALDH1A1NPC1KDM4ETP53HPGD
SCHEMBL3409104 0.86 HPGDS (0.39) BRS3ALDH1A1NPC1KDM4EGAA
SCHEMBL3398554 0.85 NPC1 (0.52) ALDH1A1NPC1RAB9ALMNAHPGDS
SCHEMBL3415257 0.85 HPGDS (0.46) ALDH1A1NPC1GAARAB9ALMNA
SCHEMBL3414984 0.85 AURKA (0.41) NPC1HPGDSMAPTKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8183380-B2 2-aminoquinolines HOFFMANN-LA ROCHE INC. (US) 2012-05-22 US claimed
EP-2262789-A1 2-AMINOQUINOLINES F. Hoffmann-La Roche AG (CH) 2010-12-22 EP claimed
WO-2009109477-A1 2-AMINOQUINOLINES F. HOFFMANN-LA ROCHE AG (CH) 2009-09-11 WO claimed
US-20090227570-A1 2-AMINOQUINOLINES HOFFMANN-LA ROCHE, INC. 2009-09-10 US claimed
US-8183380-B2 2-aminoquinolines HOFFMANN-LA ROCHE INC. (US) 2012-05-22 US disclosed
EP-2262789-A1 2-AMINOQUINOLINES F. Hoffmann-La Roche AG (CH) 2010-12-22 EP disclosed
WO-2009109477-A1 2-AMINOQUINOLINES F. HOFFMANN-LA ROCHE AG (CH) 2009-09-11 WO disclosed
US-20090227570-A1 2-AMINOQUINOLINES HOFFMANN-LA ROCHE, INC. 2009-09-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090227570-A1 2-AMINOQUINOLINES HTR5A, HTR2C, HTR2A BRS3 194/4885ALDH1A1 1203/4885NPC1 2931/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.